Comprehensive Efficacy of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin in Practical Clinical Settings: A Prospective Multi-Center Interventional Observational Study.
Alogliptin
DPP-4 inhibitor
HbA1c
type 2 diabetes
Journal
Journal of clinical medicine research
ISSN: 1918-3003
Titre abrégé: J Clin Med Res
Pays: Canada
ID NLM: 101538301
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
19
05
2020
accepted:
09
06
2020
entrez:
14
7
2020
pubmed:
14
7
2020
medline:
14
7
2020
Statut:
ppublish
Résumé
This study aimed to verify the safety and efficacy, including glycemic control, of the selective dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes. This study used a multi-center, open-label, prospective observational design. Type 2 diabetes patients who were undergoing dietary therapy and/or exercise therapy alone without sufficient glycemic control (hemoglobin A1c (HbA1c) ≥ 6.5% and < 10%) were administered alogliptin (25 mg/day). The long-term effects (6 and 12 months) on blood glucose, blood pressure, heart rate, body weight and lipids were assessed. A final 50 patients were included with a high prevalence of hypertension (77%) and dyslipidemia (72%), and a mean duration of diabetes of 4.5 years. Pre-treatment HbA1c was 7.5% and was significantly decreased at 6 and 12 months (6M: 6.4%, 12M: 6.2%; P < 0.02 vs. 0M, respectively). Body weight, blood pressure and low-density lipoprotein cholesterol were significantly decreased by 6 months and maintained at 12 months. Triglycerides showed a significant decrease at 12 months. No significant differences were observed in HbA1c decrease for different grade of age, duration of diabetes, body mass index and renal function. The degree of decrease in HbA1c was most strongly correlated with pre-treatment HbA1c. Adverse events were noted in three patients, with no serious outcomes. The blood glucose-lowering effect and safety of alogliptin were demonstrated regardless of baseline HbA1c, although its effect appeared stronger with higher pre-treatment HbA1c values. Additionally, alogliptin appears useful for managing atherosclerotic risk factors such as body weight and blood pressure.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to verify the safety and efficacy, including glycemic control, of the selective dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes.
METHODS
METHODS
This study used a multi-center, open-label, prospective observational design. Type 2 diabetes patients who were undergoing dietary therapy and/or exercise therapy alone without sufficient glycemic control (hemoglobin A1c (HbA1c) ≥ 6.5% and < 10%) were administered alogliptin (25 mg/day). The long-term effects (6 and 12 months) on blood glucose, blood pressure, heart rate, body weight and lipids were assessed.
RESULTS
RESULTS
A final 50 patients were included with a high prevalence of hypertension (77%) and dyslipidemia (72%), and a mean duration of diabetes of 4.5 years. Pre-treatment HbA1c was 7.5% and was significantly decreased at 6 and 12 months (6M: 6.4%, 12M: 6.2%; P < 0.02 vs. 0M, respectively). Body weight, blood pressure and low-density lipoprotein cholesterol were significantly decreased by 6 months and maintained at 12 months. Triglycerides showed a significant decrease at 12 months. No significant differences were observed in HbA1c decrease for different grade of age, duration of diabetes, body mass index and renal function. The degree of decrease in HbA1c was most strongly correlated with pre-treatment HbA1c. Adverse events were noted in three patients, with no serious outcomes.
CONCLUSION
CONCLUSIONS
The blood glucose-lowering effect and safety of alogliptin were demonstrated regardless of baseline HbA1c, although its effect appeared stronger with higher pre-treatment HbA1c values. Additionally, alogliptin appears useful for managing atherosclerotic risk factors such as body weight and blood pressure.
Identifiants
pubmed: 32655736
doi: 10.14740/jocmr4224
pmc: PMC7331869
doi:
Types de publication
Journal Article
Langues
eng
Pagination
423-430Informations de copyright
Copyright 2020, Takamiya et al.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Diabetes Res Clin Pract. 2012 Feb;95(2):e27-8
pubmed: 21899912
Diabetes Care. 2000 Apr;23 Suppl 2:B21-9
pubmed: 10860187
Hypertens Res. 1996 Jun;19 Suppl 1:S1-8
pubmed: 9240755
Am J Physiol Renal Physiol. 2011 Aug;301(2):F355-63
pubmed: 21593184
J Med Chem. 2007 May 17;50(10):2297-300
pubmed: 17441705
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
N Engl J Med. 2009 Jan 8;360(2):129-39
pubmed: 19092145
Clin Exp Hypertens. 2020;42(3):197-204
pubmed: 30974980
N Engl J Med. 2008 Oct 9;359(15):1577-89
pubmed: 18784090
Endocrine. 2014 May;46(1):43-51
pubmed: 24248503
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976
Diabetologia. 2012 Apr;55(4):915-25
pubmed: 22237690
Adv Ther. 2012 Jan;29(1):14-25
pubmed: 22215383
N Engl J Med. ;377(21):2097-8
pubmed: 29182247
Diabetologia. 2013 Apr;56(4):696-708
pubmed: 23344728
Diabetes Care. 2003 Mar;26(3):881-5
pubmed: 12610053
Curr Opin Nephrol Hypertens. 2011 Sep;20(5):476-81
pubmed: 21738030
Nat Med. 2013 May;19(5):567-75
pubmed: 23542788
Circulation. 2011 Nov 22;124(21):2338-49
pubmed: 22007077
Curr Opin Nephrol Hypertens. 2015 Jan;24(1):67-73
pubmed: 25415611